Clinical Trial

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Advanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have increased progression-free survival (PFS) compared to historical PFS rates for patients receiving adaptive SBRT alone.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-16
Trial Details
NCT Number NCT07126158
Lead Sponsor Washington University School of Medicine
Collaborators: Verastem, Inc., The Foundation for Barnes-Jewish Hospital
Conditions Pancreatic Adenocarcinoma, Cancer of the Pancreas, Pancreas Cancer, Pancreatic Cancer
Enrollment 36 participants
Start Date 2026-04-10
Primary Completion 2030-04-30 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-15